A carregar...
Moxetumomab pasudotox: clinical experience in relapsed/refractory hairy cell leukemia
BACKGROUND: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited. OBJECTIVES: To describe the authors’ experience of administering moxetumomab pasudotox...
Na minha lista:
| Publicado no: | Clin J Oncol Nurs |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6688475/ https://ncbi.nlm.nih.gov/pubmed/31099793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1188/19.CJON.E52-E59 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|